<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092754</url>
  </required_header>
  <id_info>
    <org_study_id>1177-01-597</org_study_id>
    <nct_id>NCT01092754</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 4 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark(R) in Pediatric Patients (2-11 &amp; 12-18 Yrs) Referred for Contrast-Enhanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to characterize the safety, efficacy and pharmacokinetic
      profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients referred for magnetic resonance imaging (MRI) of the liver or central
      nervous system (CNS) will be stratified by age to one of two groups (2 through 11 and 12
      through 18 years of age).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess efficacy by analyzing the clinical diagnosis, degree of confidence in diagnosis and level of conspicuity of lesions.</measure>
    <time_frame>Immediately before and immediately after Optimark dosing</time_frame>
    <description>Optimark is an MRI contrast. Efficacy measurements will be determined from images obtained without contrast (immediately before) and with contrast (immediately after).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of Optimark by analyzing adverse events and changes in vital signs, electrocardiograms (ECGs), physical exams, and clinical laboratory results.</measure>
    <time_frame>through 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the blood and urine PK levels of Optimark</measure>
    <time_frame>through 10 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pathological Processes</condition>
  <arm_group>
    <arm_group_label>A: Other</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Other</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>contrast enhanced MRI</description>
    <arm_group_label>A: Other</arm_group_label>
    <other_name>gadoversetamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>contrast enhanced MRI</description>
    <arm_group_label>B: Other</arm_group_label>
    <other_name>gadoversetamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadoversetamide</intervention_name>
    <description>Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .</description>
    <arm_group_label>A: Other</arm_group_label>
    <arm_group_label>B: Other</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 thru 18 years of age

          -  referred for MRI of the liver or CNS

          -  if female and of child-bearing potential, must have negative pregnancy test within 24
             hours of study drug administration

          -  if applicable, agree to use medically accepted method of contraception throughout the
             study

          -  if necessary, patients entering the PK subgroup must be willing to be housed within
             the investigational facility for a minimum of 24 hours following drug administration

          -  understand the requirements of the study and provide written consent to participate,
             agree to abide by the study requirements

        Exclusion Criteria:

          -  previously entered into this study or a previous study using Optimark

          -  received investigational drug within 30 days of admission into this study or plan to
             participate in a clinical study prior to the end of this study's monitoring period.
             (patients on a research protocol using an approved drug ar acceptable)

          -  medical condition, serious intercurrent illness, or extenuating circumstance that
             would significantly decrease study compliance and all prescribed follow up

          -  known or suspected abnormal renal function for age or requiring dialysis during the
             study period

          -  pregnant or breastfeeding

          -  scheduled to undergo any contrast-enhanced examination within 7 days prior to baseline
             examination or during the course of this study period

          -  condition that is a contraindication to MRI (i.e., cardiac pacemaker, epicardial
             pacemaker leads, cochlear implants, ferromagnetic aneurysm clip, ferromagnetic halo
             device, or other condition that would preclude patient proximity to a strong external
             magnetic field)

          -  experienced a previous hypersensitivity reaction to a gadolinium-based contrast agent

          -  recent history of hemolytic anemia, sickle cell anemia, or other hemoglobinopathy

          -  undergone a surgical procedure within one week prior to study admission or are planned
             to undergo a surgical procedure during study participation (central line placement is
             acceptable)

          -  history of significant claustrophobia

          -  weighs less than 25 lbs (11 kgs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddie Darton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Childrens Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Sciences Center- Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Childrens Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Childrens Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <name_title>Eddie Darton, Jr., M.D./Director, Global Drug Safety &amp; PVG</name_title>
    <organization>Mallinckrodt Inc.</organization>
  </responsible_party>
  <keyword>brain, spine, liver, MRI, Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pathologic Processes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

